Furthermore, APP/PS1 double-transgenic mice treated with AP39 observed an improvement in their learning and memory impairments [49] suggesting that H2S, targeted to the mitochondria, could be a potential therapeutic candidate for AD. This evidence concerns the gene APP and Alzheimer disease.